Australia's sky could change forever after winter ends
When Aussies look up into the sky at the end of winter, there will be a noticeable difference from what we saw a decade ago. Bogong moths used to migrate across Victoria, NSW, Queensland and South Australia in their billions, reportedly blocking out the moon, but in 2017 and 2018 their numbers crashed by 99.5 per cent.
Mortein once advertised its sprays could be used to kill bogong moths, but that advice was eventually removed after the species was listed as endangered in 2021. While the moths have been in steady decline since the 1980s, it was the sudden drop in numbers during the Millennium Drought that caused the average punter to take notice.
The situation has a leading conservation biologist 'extremely worried' both about the moth and the animals that depend on it as a food source, like the critically endangered mountain pygmy possum. Dr Marissa Parrott from Zoos Victoria said it's accurate to say 'within a generation, Australia has changed' as invertebrates vanish from the landscape.
'In Australia, with animals like the bogong moth, it becomes apparent things can go wrong very quickly,' she told Yahoo News.
For thousands of years, bongog moths have meant spring was here, and Christmas beetles were a sign of summer. These insects are wound up in memories from our childhoods, but today both are seldom seen.
'[Insect] numbers are all declining across time. But then you get those big events like a major drought, flood or bushfires and they can wipe out entire species,' Dr Parrott said.
'We're seeing that every day, that these animals are struggling, and we've probably lost far more invertebrates than we could ever even imagine… and it's only getting worse. We really need to change.'
Parrott notes the problem is a global one, with many referring to it as an 'intertebrate apocalypse'. Often, people don't realise the insects are gone until their crops stop being pollinated or the birds that eat insects suddenly vanish.
When it comes to bogong moths, the good news is that since 2018, there has been a trend towards recovery. But the species' future is far from secure.
Zoos Victoria's Moth Tracker project, an online platform where people around the country can report bogong moth sightings, was launched in 2019, and last year was its best season on record. Between September and December, there were 1,956 sightings, and 1,089 were verified by the expert team.
Some swarms (groups of over 100 moths) were even observed in 2024, something that hadn't been seen in years. "It was wonderful to see that again, but they're only one more drought from those numbers dropping right back low again. We need to have a long-term plan to protect and recover them," Parrott said.
Related: 🚨 Call to protect Australia's changing insect landscape
A bogong moth will live for around a year, with each dying after the autumn breeding season. The caterpillars live underground throughout the winter and then migrate up to 1,000km across Australia to alpine regions in the warmer months. Those that survive the feeding frenzy from native animals fly back across the country to their breeding ground to lay their own eggs.
'Each female can lay up to 2,000 eggs, so their numbers could bounce back quite quickly if we can protect them,' Parrott said.
🌏 'Shocking' jellyfish find could change the way Aussies visit the beach
🔍 Rare find inside ancient cave after tourists banned for years
🏡 Key detail caught on front yard security footage sparks alarm
Earlier this week, a new study published in the journal Nature revealed bogong moths used constellations of stars and the Milky Way to navigate their migration routes. This upended a belief that moths simply flew towards the brightest light in the sky.
The team from Lund University, the Australian National University (ANU), and the University of South Australia compared their abilities to those of migratory birds.
Insects like bogong moths face multiple threats, including pesticides for agriculture, deforestation, climate change and light pollution. A 2017 study of select conservation areas in Germany found the insect biomass had dropped by 75 per cent in 27 years.
Love Australia's weird and wonderful environment? 🐊🦘😳 Get our new newsletter showcasing the week's best stories.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix', 'the Company') today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved a label expansion for Illuccix® (kit for the preparation of gallium Ga-68 gozetotide, for injection) to include patient selection for radioligand therapy (RLT) in the pre-taxane setting. The update applies to Illuccix's third indication, for selection of patients who are indicated for PSMA1-directed therapy as described in the Prescribing Information of the therapeutic products. The label expansion follows the FDA's approval of an expanded label for Pluvicto®2 (lutetium Lu177 vipivotide tetraxetan) for use in metastatic castration-resistant prostate cancer (mCRPC) patients after treatment with androgen receptor pathway inhibitor (ARPI) therapy and before chemotherapy3. With RLT now approved for use earlier in the patient journey, the clinical utilization of Illuccix® is expected to increase by at least 20,000 scans annually4. Scott T. Tagawa, MD, a genitourinary (GU) oncologist in New York said, 'It is pleasing to see the ability to use gallium-68 PSMA-PET for patient selection expanded. This empowers clinicians to make more informed, personalized decisions earlier in the disease course and access life-prolonging targeted radionuclide therapy for more patients with prostate cancer.' Kevin Richardson, Chief Executive Officer, Precision Medicine, Telix, said, 'We're pleased that the U.S. label for Illuccix has been expanded to support patient selection for RLT in the pre-taxane setting, aligning with the evolving treatment landscape. PSMA-PET imaging has become a standard of care in the detection and management of prostate cancer. With this update, patients can now benefit from the high diagnostic accuracy of Illuccix to identify those most likely to respond to PSMA-targeted therapy, even earlier in their treatment journey.' INDICATIONS AND USAGE Illuccix, after radiolabeling with Ga 68, is for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: With suspected metastasis who are candidates for initial definitive therapy With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level For selection of patients who are indicated for PSMA-directed therapy as described in the Prescribing Information of the therapeutic products IMPORTANT SAFETY INFORMATIONWARNINGS AND PRECAUTIONS Risk for MisinterpretationImage interpretation errors can occur with Illuccix PET. A negative image does not rule out the presence of prostate cancer, and a positive image does not confirm the presence of prostate cancer. Gallium Ga 68 gozetotide uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes such as Paget's disease, fibrous dysplasia, and osteophytosis. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended. Imaging Prior to Initial Definitive or Suspected Recurrence TherapyThe performance of Illuccix for imaging of biochemically recurrent prostate cancer seems to be affected by serum PSA levels and by site of disease. The performance of Illuccix for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by Gleason score. Radiation RisksGallium Ga 68 gozetotide contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and healthcare providers. Advise patients to hydrate before and after administration and to void frequently after administration. ADVERSE REACTIONSThe safety of gallium Ga 68 gozetotide was evaluated in 960 patients in the PSMA-PreRP and PSMA-BCR studies, each receiving one dose of gallium Ga 68 gozetotide. The average injected activity was 188.7 ± 40.7 MBq (5.1 ± 1.1 mCi). The most commonly reported adverse reactions were nausea, diarrhea, and dizziness, occurring at a rate of <1%.In the VISION study, 1003 patients received one dose of gallium Ga 68 gozetotide intravenously with the amount of radioactivity 167.1 ± 23.1 MBq (4.52 ± 0.62 mCi). Adverse reactions occurring at ≥0.5% in patients with metastatic prostate cancer who received gallium Ga 68 gozetotide injection in the clinical study were fatigue (1.2%), nausea (0.8%), constipation (0.5%), and vomiting (0.5%). Adverse reactions occurring at a rate of < 0.5% in the VISION study were diarrhea, dry mouth, injection site reactions, including injection site hematoma and injection site warmth and chills. DRUG INTERACTIONSAndrogen deprivation therapy and other therapies targeting the androgen pathwayAndrogen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, can result in changes in uptake of gallium Ga 68 gozetotide in prostate cancer. The effect of these therapies on performance of gallium Ga 68 gozetotide PET has not been established. Please note that this information is not see the Full Prescribing Information . You are encouraged to report suspected adverse reactions of prescription drugs to the FDA. Visit MedWatch at or call 1-800-FDA-1088. You may also report adverse reactions to Telix by calling 1-844-455-8638 or emailing: pharmacovigilance@ Dr. Tagawa has served as a paid consultant to Telix and his institution has received research funding. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: Telix Media Relations (U.S.) Eliza Schleifstein ES Media Relations Email: eliza@ Phone: 917-763-8106 About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's first generation PSMA-PET imaging agent, is approved and commercially available in multiple countries globally. Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the U.S. FDA5. Visit for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 'may', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'outlook', 'forecast' and 'guidance', or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country. _________________________1 Prostate-specific membrane antigen2 Pluvicto is a registered trademark of Novartis AG and/or its affiliates.3 28 March 2025, FDA Statement: for patients who have been treated with ARPI therapy and are considered appropriate to delay taxane-based chemotherapy.4 Based on licensed indication for Pluvicto in mCRPC patients who have been treated with androgen receptor (AR) pathway inhibition.5 Telix ASX disclosure 21 March 2025.
Yahoo
2 hours ago
- Yahoo
Scientists Confirm Identity of Infamous, Centuries-Old Shipwreck
Scientists at the Australian National Maritime Museum (ANMM) have announced after more than 20 years of research that they have definitively identified the HMS Endeavour, one of the most famous shipwrecks of all time, The Guardian reported. However, the identification has led to some controversy with American scientists. The Endeavour was sunk off the coast of Newport, Rhode Island, during the Revolutionary War, though no one knew the exact location for centuries. It wasn't until the late 1990s that researchers considered one of the wrecks off of Newport might be the Endeavour. In 2000, the ANMM began their investigation of the wreck, though only 15 percent of the ship was recovered from the bottom of the Atlantic. After 25 years of work, ANMM researchers feel they have definitively proven that the Newport wreck is the HMS Endeavour. Citing the use of timber matches as well as site overlays on original designs and shipbuilding details, the ANMM called the results 'the culmination of 25 years of detailed and meticulous archaeological study on this important vessel. It has involved underwater investigation in the US and extensive research in institutions across the globe. This final report marks our definitive statement on the project.' However, the Rhode Island Marine Archaeology Project (RIMAP), a longtime collaborator on the research, has accused the ANMM of allowing 'Australian politics or emotions' to cloud the results. 'There are numerous questions that remain unanswered that could reverse such an identification,' said RIMAP director Kathy Abbass without elaborating. Regardless of which country is correct, the ANMM has called for an immediate conservation of the vessel, citing the deterioration it's experienced over time due to marine life and other ecological factors. Scientists Confirm Identity of Infamous, Centuries-Old Shipwreck first appeared on Men's Journal on Jun 22, 2025
Medscape
9 hours ago
- Medscape
CMR in MINOCA Linked to Improved Diagnosis and Management
TOPLINE: In a prospective study of over 300 patients with myocardial infarction with nonobstructive coronary arteries (MINOCA), cardiovascular magnetic resonance (CMR) was associated with meaningful changes in clinical diagnosis and/or management in 63% of patients and a similar increase in diagnostic certainty. METHODOLOGY: Previous CMR studies in MINOCA have focused on radiologic yield — a limited metric that does not reflect real‐world clinical utility. Prospective data on patient care are lacking. This prospective study conducted in Australia and the UK assessed the impact of CMR on diagnosis and management in 320 patients with MINOCA (mean age, 55.6 years; 52% men) recruited between January 2019 and July 2023. Patients were included if they had a hospital admission with acute features consistent with the Fourth Universal Definition of Myocardial Infarction, no obstructive coronary artery disease on angiography, and a clinician assessment indicating acute myocardial infarction as the most likely presentation. The treating cardiologists completed a questionnaire before and after CMR to record their working diagnosis, rate diagnostic certainty on a 1-10 scale (10 = most certain), and specify intended management, including medications and follow-up testing. The primary endpoint was a composite of change in clinical diagnosis or management after CMR. TAKEAWAY: CMR was associated with a change in diagnosis or management in 63% of patients (P < .001), with diagnosis revised in 38% and management changed in 50%. Diagnostic certainty increased significantly from a median score of 6-8 after CMR (P < .001), and diagnostic confidence numerically increased in 63% of patients. The absence of coronary atheroma, a pre-CMR diagnostic certainty score ≤ 5, and early CMR (performed within 14 days of hospital presentation) independently predicted a change in diagnosis or management, with 80% of patients with all three predictors vs 40% of those with none meeting the primary outcome. Of 172 patients initially prescribed dual antiplatelet therapy, 66 (38%) had it deprescribed following CMR, yielding a number needed to test of 3. IN PRACTICE: 'Integration of CMR into diagnostic imaging pathways may be reasonable to augment clinical diagnosis and management; however, further cost-effectiveness analyses are now warranted,' the study authors wrote. SOURCE: This study was led by Adil Rajwani, PhD, of the Royal Perth Hospital, Perth, Australia. It was published online on June 13, 2025, in Heart. LIMITATIONS: The study was limited by the impracticality of conducting a bias-free randomized trial of CMR vs no CMR. It was also limited by the assessment of CMR's impact only immediately after imaging, potentially missing later clinical insights. Medication protocols were not standardized, and the limited use of additional diagnostics such as optical coherence tomography may have influenced the findings. DISCLOSURES: This study was funded by a grant from the Royal Perth Hospital Medical Research Foundation in Australia. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
